Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00978952




Registration number
NCT00978952
Ethics application status
Date submitted
14/09/2009
Date registered
17/09/2009

Titles & IDs
Public title
Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta
Scientific title
Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta
Secondary ID [1] 0 0
803
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coarctation of the Aorta 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Large Diameter Advanta™ V12 Covered Stent

Experimental: Investigational Group - Use of Large Diameter Advanta™ V12 Covered Stent.


Treatment: Devices: Large Diameter Advanta™ V12 Covered Stent
Stent placement
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary Efficacy
Timepoint [1] 0 0
12 month
Primary outcome [2] 0 0
Primary Safety
Timepoint [2] 0 0
30 days of procedure
Secondary outcome [1] 0 0
Secondary Safety
Timepoint [1] 0 0
procedural (time zero)
Secondary outcome [2] 0 0
Secondary Safety
Timepoint [2] 0 0
12 month
Secondary outcome [3] 0 0
Secondary Safety
Timepoint [3] 0 0
12 months

Eligibility
Key inclusion criteria
* Patients with a presence of native or recurrent coarctation of the aorta as confirmed by blood pressure gradient, 2D-echocardiography with Doppler or angiography.
* Subject weighs a minimum of 30 kg.
* The peak pressure gradient is =20 mmHg systolic blood pressure across the coarctation site.
* Vessels at access site can accept a minimum size of 9 French for a 12 mm balloon and 11 French for a 14 and 16 mm balloon.
* Coarctation can be successfully crossed with a guide wire, sheath and device.
* Diameter of transverse arch distal to left subclavian artery is between 9.5 mm and 20 mm in diameter.
* Subject is able and willing to adhere to all required follow-up visits and testing.
* Subject is able and willing to adhere to the required follow-up medication regimen.
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* The physician is not able to access the coarctation with standard techniques.
* Presence of other thoracic aortic arterial lesions or aneurysms requiring treatment within 30 days of the implant procedure.
* Length of coarctation is greater than 45 mm in length.
* Connective tissue and genetic disorders, including William, Marfan, Turner, Noonan syndrome.
* The coarctation has adjacent, acute thrombus.
* The coarctation was previously treated with a stent.
* Proximity of the coarctation to an important side branch resulting in crossing of the side branch with the Large Diameter Advanta™ V12 Covered Stent device (e.g. "jailing" of the branch vessel).
* Subject has a tubular graft, interposition graft, stent graft at or near the coarctation site that would be interfere with delivery, positioning, expansion or stabilization of the Large Diameter Advanta™ V12 Covered Stent
* Subject has contrast agent hypersensitivity that cannot be adequately premedicated, has a hypersensitivity to stainless steel, expanded polytetrafluoroethylene (ePTFE) or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications.
* Bloodstream infection
* Subject is pregnant or breastfeeding.
* Subject has a co-morbid illness that may result in a life expectancy of less than 1 year.
* The investigator deems the subject to be an inappropriate candidate for the study.
* Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now approved product are not excluded by this criterion.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2017
Sample size
Target
Accrual to date
Final
70
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Children's Hospital at Westmead - Sydney
Recruitment postcode(s) [1] 0 0
2145 - Sydney
Recruitment outside Australia
Country [1] 0 0
Brazil
State/province [1] 0 0
Sao Paulo
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario
Country [3] 0 0
Germany
State/province [3] 0 0
Berlin
Country [4] 0 0
Germany
State/province [4] 0 0
Frankfurt
Country [5] 0 0
Germany
State/province [5] 0 0
Sankt Augustin
Country [6] 0 0
Israel
State/province [6] 0 0
Petach Tikva
Country [7] 0 0
Italy
State/province [7] 0 0
Milan
Country [8] 0 0
United Kingdom
State/province [8] 0 0
Bristol

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Atrium Medical Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Elchanan Bruckheimer, MD
Address 0 0
Schneider Children's Medical Center, Israel
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT00978952